On Apr. 17, 2020, Sinovac Biotech announced that the Company had commenced Phase I clinical trial, a randomized, double-blinded, placebo controlled study, for its vaccine candidate against COVID-19. Enrollment of the first group of volunteers and the first dose of vaccination for these volunteers had been completed.